Association of UGT1A9 Polymorphisms with Cardiac Injury Biomarkers and Clinical Features

Area of Science:

• Pharmacogenetics
• Cardiology
• Biochemistry

Background:

• Cardiac biomarkers are crucial for diagnosing myocardial injury.
• UGT1A9 enzyme activity can be affected by genetic polymorphisms.
• Variability in biomarker levels can complicate clinical assessment.

Purpose of the Study:

• To investigate the association between UGT1A9 gene polymorphisms and cardiac biomarker profiles.
• To determine if UGT1A9 variations influence clinical presentations in patients with cardiac symptoms.
• To evaluate the impact of UGT1A9 genotypes on CK-MB and Troponin I levels.

Main Methods:

• Genotyping of UGT1A9 alleles (*1, *2, *3) using allele-specific PCR and TaqMan assays.
• Classification of patients into wild-type (wt/wt), heterozygous (wt/*3), and homozygous (*3/*3) UGT1A9 genotype groups.
• Statistical analysis using Kruskal-Wallis, Mann-Whitney U, and chi-square tests to compare biomarker levels across genotypes.

Main Results:

• Genotype distribution: 64% wt/wt, 32% wt/*3, 4% *3/*3.
• Significant differences in CK-MB levels across UGT1A9 genotypes (p=0.006), with highest levels in wt/*3 carriers.
• No significant genotypic differences observed for Troponin I levels (p=0.533).

Conclusions:

• UGT1A9 polymorphisms, specifically the *3 allele, are associated with altered CK-MB levels, potentially confounding myocardial injury assessment.
• Troponin I levels are not significantly affected by UGT1A9 genotype.
• Pharmacogenetic testing for UGT1A9 may enhance understanding of biomarker variability and guide personalized treatment strategies.